Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 17;12(4):494-502.
doi: 10.1093/ckj/sfy117. eCollection 2019 Aug.

MYH9-related disorders display heterogeneous kidney involvement and outcome

Affiliations

MYH9-related disorders display heterogeneous kidney involvement and outcome

Nahid Tabibzadeh et al. Clin Kidney J. .

Abstract

Background: MYH9-related diseases (MYH9-RD) are autosomal dominant disorders caused by mutations of the MYH9 gene encoding the non-muscle myosin heavy chain IIA. They are characterized by congenital thrombocytopenia, giant platelets and leucocyte inclusions. Hearing impairment, pre-senile cataract and nephropathy can also occur. We aimed to evaluate renal involvement and outcome in MYH9-RD patients followed-up by nephrologists.

Methods: We conducted a retrospective multicentre observational study of 13 patients among 9 families with MYH9 mutation diagnosed by genetic testing and immunofluorescence assay referred to nephrologists.

Results: At initial referral, median age was 30 (range 14-76) years. Median estimated glomerular filtration rate was 66 mL/min/1.73 m2 (0-141) and two patients had already end-stage renal disease (ESRD). Renal presentation associated proteinuria (n = 12), haematuria (n = 6) and hypertension (n = 6). Three patients developed a rapid onset ESRD whereas five others had a relatively stable kidney function over a 3-year median follow-up (1-34). Extra-renal features varied widely, with hearing impairment in six patients, cataract in two and mild liver dysfunction in seven. Thrombocytopenia existed at referral in 11 patients. Time to diagnosis varied from 0 to 29 years (median 3 years). Initial diagnoses such as idiopathic thrombocytopenic purpura (n = 4) and focal segmental glomerulosclerosis (n = 1) led to corticosteroid administration (n = 4), intravenous immunoglobulins (n = 3), cyclophosphamide (n = 1) and splenectomy (n = 1).

Conclusions: Renal involvement and outcome in MYH9-RD are heterogeneous. The diagnosis is often delayed and misdiagnoses can lead to unnecessary treatments. MYH9-RD should be considered in any patient with glomerular involvement associated with a low or slightly decreased platelet count and/or hearing loss and liver dysfunction.

Keywords: FSGS; MYH9; deafness; hereditary nephropathy; thrombocytopenia.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Pedigree chart of the Family A. Proband’s (Patient 1) grandfather died at the age of 82 years of so-called ‘uraemia’. The bottom right part of each box (in plain black) corresponds to renal involvement; the bottom left part (in fine stripes) to thrombocytopenia and the upper right part (in large stripes) to hearing disability.

References

    1. Althaus K, Greinacher A.. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189–203 - PubMed
    1. Hegglin R. Gleichzeitige konstitutionelle Veranderungen an Neutrophilen und Thrombozyten. Helv Med Acta 1945; 12: 439. - PubMed
    1. Lusher JM, Schneider J, Mizukami I. et al. The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies. Blood 1968; 32: 950–961 - PubMed
    1. Epstein CJ, Sahud MA, Piel CF. et al. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 1972; 52: 299–310 - PubMed
    1. Peterson LC, Rao KV, Crosson JT. et al. Fechtner syndrome–a variant of Alport’s syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65: 397–406 - PubMed